Abstract
Compliance Aids have gained widespread use to assist patients in managing their medicines, with a view to addressing the issue of adherence. However, although patient outcomes may have been improved through better use of compliance aids, it has been highlighted that there are limited data on the stability of medicines, when removed from the original container and repackaged in a compliance aid. Exposure of medicines to heat, light, moisture and air (oxygen) may impact on both their chemical and physical stability, resulting in the potential for quality of the medicine and thus the safety for the patient being compromised. It is also uncertain whether the compliance aid can provide the same protection from these environmental conditions as the manufacturer’s packaging, even though the time frame for repackaging is only 28 days. This paper presents a comprehensive review and detailed discussion of the available literature on the stability implications of repackaging medicines into compliance aids. The importance of repackaging is thus highlighted by its ability to impact on therapeutic outcomes for patients.
Keywords: Dose Administration Aids, quality, repackaging, safety, stability, storage.
Current Drug Safety
Title:Evidence of Stability of Medicines Repackaged in Compliance Aids: A Review
Volume: 11 Issue: 1
Author(s): Alison Haywood and Beverley D. Glass
Affiliation:
Keywords: Dose Administration Aids, quality, repackaging, safety, stability, storage.
Abstract: Compliance Aids have gained widespread use to assist patients in managing their medicines, with a view to addressing the issue of adherence. However, although patient outcomes may have been improved through better use of compliance aids, it has been highlighted that there are limited data on the stability of medicines, when removed from the original container and repackaged in a compliance aid. Exposure of medicines to heat, light, moisture and air (oxygen) may impact on both their chemical and physical stability, resulting in the potential for quality of the medicine and thus the safety for the patient being compromised. It is also uncertain whether the compliance aid can provide the same protection from these environmental conditions as the manufacturer’s packaging, even though the time frame for repackaging is only 28 days. This paper presents a comprehensive review and detailed discussion of the available literature on the stability implications of repackaging medicines into compliance aids. The importance of repackaging is thus highlighted by its ability to impact on therapeutic outcomes for patients.
Export Options
About this article
Cite this article as:
Haywood Alison and Glass D. Beverley, Evidence of Stability of Medicines Repackaged in Compliance Aids: A Review, Current Drug Safety 2016; 11 (1) . https://dx.doi.org/10.2174/1574886310666150928104931
DOI https://dx.doi.org/10.2174/1574886310666150928104931 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Platelets in Athero-Thrombotic Events
Current Pharmaceutical Design Protein Kinases and their Modulation in the Central Nervous System
Current Medicinal Chemistry - Central Nervous System Agents Musculoskeletal Adverse Drug Reactions: A Review of Literature and Data from ADR Spontaneous Reporting Databases
Current Drug Safety Aortic Dissection: A Review of the Pathophysiology, Management and Prospective Advances
Current Cardiology Reviews Kounis Syndrome Following Beta-Lactam Antibiotic Use: Review of Literature
Inflammation & Allergy - Drug Targets (Discontinued) MDMA Toxicity and Pathological Consequences: A Review About Experimental Data and Autopsy Findings
Current Pharmaceutical Biotechnology In the Search of the Vulnerable Plaque: Current Diagnostic Techniques and Future Directions
Vascular Disease Prevention (Discontinued) Editorial (Hot Topic: Platelets in Vascular Homeostasis and Inflammation: Current Perspectives from Bench to Bedside)
Current Vascular Pharmacology Contrast Echocardiography: An Update on Clinical Applications
Current Pharmaceutical Design Targeting the Inflammatory Response in Healing Myocardial Infarcts
Current Medicinal Chemistry Mitochondrial Dynamics: An Emerging Paradigm in Ischemia-Reperfusion Injury
Current Pharmaceutical Design Role of Mitochondrial Translocator Protein (18 kDa) on Mitochondrial- Related Cell Death Processes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Challenges in Managing Amniotic Fluid Embolism: An Up-to-Date Perspective on Diagnostic Testing with Focus on Novel Biomarkers and Avenues for Future Research
Current Pharmaceutical Biotechnology Inflammation and Anemia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Assessment of Vascular Geometry for Bilateral Carotid Artery Ligation to Induce Early Basilar Terminus Aneurysmal Remodeling in Rats
Current Neurovascular Research Is there a Relationship between Endothelial Dysfunction of the Brachial Artery, Carotid Intima-Media Thickness and Soluble Receptors of Tumor Necrosis Factor-Alpha?
Vascular Disease Prevention (Discontinued) Extracorporeal Lung Assist for Sepsis and Acute Respiratory Distress Syndrome
Cardiovascular & Hematological Disorders-Drug Targets Stable Angina Pectoris: Current Medical Treatment
Current Pharmaceutical Design Different Effects of Thiazolidinediones on Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus: Pioglitazone vs Rosiglitazone
Current Drug Safety Aspirin Resistance in Cardiovascular Disease: Pathogenesis, Diagnosis and Clinical Impact
Current Pharmaceutical Design